CytoDyn Operating Expenses 2010-2024 | CYDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CytoDyn operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CytoDyn operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$87.5B
Takeda Pharmaceutical (TAK)	$47.5B
Merck (MKGAF)	$24.4B
Astellas Pharma (ALPMY)	$22B
Sandoz Group AG (SDZNY)	$17.6B
Summit Therapeutics (SMMT)	$16.8B
United Therapeutics (UTHR)	$15.6B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$12.2B
Catalent (CTLT)	$10.9B
Revolution Medicines (RVMD)	$7.7B
Orion OYJ (ORINY)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$4.3B
Corcept Therapeutics (CORT)	$4.3B
Dyne Therapeutics (DYN)	$3.7B
PTC Therapeutics (PTCT)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Xencor (XNCR)	$1.7B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B